225Ac-DOTA-CCK-66

N/A

Report date: 2025/11/20 16:04:05

NME

Base Information

Drug Name225Ac-DOTA-CCK-66

Drug Alias Name225Ac-labeled minigastrin analog DOTA-CCK-66

ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionCholecystokinin B receptor antagonists

TargetsCholecystokinin B receptor

Therapy Area/IndicationsMedullary thyroid cancer (MTC)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTechnical University Of Munich

China Registration ClassN/A

Develop Information

Active CompaniesTechnical University Of Munich

Inactive CompaniesN/A

Active IndicationsMedullary thyroid cancer (MTC)

Inactive IndicationsN/A

Other Information

ATC CodeN/A